Healthy Skepticism Library item: 2303
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Lehner JP, Meyer F, Juillet Y.
[Communication and transparency concerning risk-benefit analysis in public health: the example of medication]
Therapie. 2001 Jul-Aug;56(4):335-9 2002 Jul-Aug 01; 56:(4):335-9
Abstract:
As far as communication of the evaluation of risk benefit assessment of medications is concerned, validated and interpreted data only have to be taken into account. Free access to information by the public has to be considered seriously and there is now a real and strong demand. This situation has to be viewed in parallel with the huge development of websites communicating information on health issues. This report summarizes the discussion between the authorities and pharmaceutical companies and reports the different concrete proposals that emerged
Keywords:
MeSH Terms:
Adverse Drug Reaction Reporting Systems
Clinical Trials
Congresses
Consumer Satisfaction
Disclosure*
Drug Evaluation*
Drug Industry*
Drug Information Services*/standards
English Abstract
France
Humans
Internet
Mass Media
Patient Education*
Pharmaceutical Preparations/adverse effects
Risk Assessment
